SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Durata Therapeutics, Inc. in Connection with the Sale of the Company

BALA CYNWYD, Pa.--()--Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Durata Therapeutics, Inc. (“Durata” or the “Company”) (Nasdaq: DRTX) relating to the proposed acquisition by Actavis plc.

Click here to learn more about the investigation http://brodsky-smith.com/836-drtx-durata-therapeutics-inc.html, or call: 877-534-2590. There is no cost or obligation to you.

Under the terms of the transaction, Durata shareholders will receive only $23.00 in cash for each share of Durata common stock they own. In addition, stockholders of Durata will receive one Contingent Value Right (CVR) which will entitled the holder to receive an additional cash payment of up to $5.00 per share if certain milestones are reached. However, there is no guarantee that these milestones will ever be reached.

The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Durata for not acting in the Company’s shareholders best interests in connection with the sale process. The transaction may undervalue Durata as the Company recently announced a summary of presentation data from its recently launched product DALVANCE ™ (dalbavancin). Among the positive findings was data supporting further study in Patients with osteomyelitis and prosthetic joint infections. A separate analysis was also positive for patients with ABASSSI that were treated with dalbavancin.

If you own shares of Durata common stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, by visiting http://brodsky-smith.com/836-drtx-durata-therapeutics-inc.html, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and case action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Contacts

Brodsky & Smith, LLC
Jason L. Brodsky, Esquire
Evan J. Smith, Esquire
877-LEGAL-90
investorrelations@brodsky-smith.com
http://brodsky-smith.com/836-drtx-durata-therapeutics-inc.html

Contacts

Brodsky & Smith, LLC
Jason L. Brodsky, Esquire
Evan J. Smith, Esquire
877-LEGAL-90
investorrelations@brodsky-smith.com
http://brodsky-smith.com/836-drtx-durata-therapeutics-inc.html